BPH Corporate Ltd (ASX: BPH) investee company Cortical Dynamics Ltd (“Cortical”), has presented a poster entitled “Propofol and Remifentanil Differentially Modulate Frontal Electroencephalographic Activity” at the 2010 Annual Meeting of the American Society of Anesthesiologists in San Diego.
Professor David Liley of Cortical commented that ”based on the number of companies exhibiting depth of anaesthesia monitoring solutions and scientific papers evaluating such monitors it is quite clear that brain function monitoring continues to grow in importance for the safe and effective practice of anaesthesia.”
The BAR monitoring system utilises a number of innovative developments to better monitor brain function that emerge out of recent advances in our understanding of how the brain's rhythmic electrical activity, the electroencephalogram (EEG), is produced. The approach used is fundamentally different from all other devices currently available in the market in that its underlying algorithm produces EEG indexes which are directly related to the physiological state of the patient's brain. Other systems on the market produce EEG measures based on physiologically arbitrary statistical methods that utilise the trial-and-error identification of anaesthetic induced EEG regularities in patients undergoing a variety of operative procedures.
The BAR system provides much greater sensitivity to anaesthetic drug effect enabling the monitoring of a wider range of anaesthetic agents, some of which are not properly detected by the competing technologies. The physiological underpinnings of the BAR monitoring system makes it particularly relevant to quantifying changes in brain function that attend the early onset of a range of degenerative neurological illnesses such as Alzheimer's dementia.
BPH has an interest in the medical devices sector and is currently working towards the commercialisation of the BAR monitoring system for the measurement and monitoring of patient brain activity during anaesthesia as well as in conditions of health and disease. Cortical is working towards listing on the Australian Securities
David Breeze
Chairman
Download this document
